
Please try another search
I-Mab, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.
Name | Age | Since | Title |
---|---|---|---|
Xi Liu | - | 2021 | Independent Director |
Wei Fu | 42 | 2018 | Chairman |
Jun Ma | - | 2020 | Member of Scientific Advisory Board |
Lielie Zhang | - | 2024 | Independent Director |
Xi-Yong Fu | 53 | 2024 | CEO & Director |
Patricia M. LoRusso | - | 2019 | Member of Scientific Advisory Board |
Chun Kwok Au | 52 | 2020 | Independent Director |
Roy Steven Herbst | 62 | 2019 | Member of Scientific Advisory Board |
Eric K. Rowinsky | 68 | 2019 | Member of Scientific Advisory Board |
Chia-Hung Yang | 62 | 2020 | Independent Director |
Sean Wuxiong Cao | - | 2025 | Independent Director |
Howard L. Weiner | 78 | 2019 | Member of Scientific Advisory Board |
Timothy A. Yap | 50 | 2019 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review